कंपनी का अवलोकन
Castle Biosciences, Inc. is a molecular diagnostics entity that provides specialized test solutions designed for the diagnosis and treatment of specific medical conditions, including dermatologic cancers, Barrett's esophagus, atopic dermatitis, and uveal melanoma. The corporation operates within the Healthcare sector and specifically functions in the Diagnostics & Research industry, a domain focused on developing technologies to assist in clinical decision-making and patient outcomes. This organization maintains a significant operational scale with a total market capitalization of $709.83M, an annual revenue of $344.23M, and an employee base of 883 individuals. The combination of a $709.83M market cap and $344.23M in revenue indicates that the company holds a substantial position in the market, possessing sufficient capital resources to fund its research initiatives and maintain a large workforce dedicated to diagnostic innovation.
वित्तीय स्वास्थ्य
The company reported a total revenue of $344.23M over the trailing twelve months, yet recorded a net income of -$24,158,000 and an EBITDA of -$2,039,000, revealing a distinct gap between top-line sales and bottom-line profitability driven by significant operating expenses. Despite the negative net income, the entity generated a positive free cash flow of $41.21M, which signifies a strong capacity for financial flexibility and the ability to fund operations without immediate external financing. The gross margin stands at 79.4%, indicating highly efficient production or sales of diagnostic kits, while the operating margin of -4.4% and profit margin of -7.0% suggest that high fixed costs or research expenditures are currently suppressing overall profitability. On the balance sheet, the company holds $299.50M in cash against $37.02M in debt, resulting in a debt-to-equity ratio of 7.86, which implies a highly leveraged capital structure where equity is relatively small compared to long-term obligations. Liquidity is robust, evidenced by a current ratio of 5.26, indicating that the firm holds more than five times the current assets necessary to cover its short-term liabilities. Furthermore, the return on equity is -5.2% and the return on assets is -2.6%, metrics that reveal that management has not yet generated positive returns on the capital invested in the business, reflecting the typical losses incurred during the development and expansion phases of a biotech firm.
मूल्यांकन आकलन
Castle Biosciences, Inc. currently exhibits a P/E ratio (TTM) that is effectively N/A due to negative earnings, while the forward P/E stands at -43.09, a figure that implies the market is pricing in significant future earnings recovery rather than current profitability. The price-to-book ratio is recorded at 1.48, suggesting that the market values the company's equity at 48% above its book value, reflecting expectations of future growth or intangible asset value despite current losses. Alternative valuation metrics show a price-to-sales ratio of 2.06 and an EV/EBITDA of -212.90, indicating that the stock is priced based on revenue multiples rather than earnings, which is common for pre-profitability healthcare companies with high revenue but negative adjusted earnings. The stock has traded within a 52-week range between a low of $14.59 and a high of $44.28, with the current valuation position relative to this historical volatility requiring analysis of the forward P/E context. The beta value is 1.19, meaning the stock's price volatility is 19% higher than the broader market, exposing investors to greater fluctuations than large-cap stable healthcare peers.
Growth & Income
The company's revenue growth for the year-over-year period is 0.8%, while the earnings growth rate is N/A due to the negative net income, indicating that the business is in a phase where revenue expansion is outpacing any potential for immediate earnings growth. As a non-dividend payer, the company has a dividend yield of N/A and a payout ratio of 0.0%, confirming that the firm reinvests all available earnings and cash reserves into research and development rather than distributing income to shareholders. This strategy aligns with the industry norms for diagnostics companies that prioritize funding new test solutions and clinical trials over providing current income streams. The overall growth and income profile characterizes a capital-intensive enterprise trading on revenue multiples with zero current dividend yield, relying entirely on future operational leverage to eventually achieve positive earnings growth.